(±)- 18-methoxycoronaridine: A novel Iboga alkaloid congener having potential anti-addictive efficacy

CNS Drug Reviews

Volumn 5, Issue 1, 1999, Pages 27-42

  Glick, Stanley D ^a   Maisonneuve, Isabelle M ^a   Hough, Lindsay B ^a   Kuehne, Martin E ^b   Bandarage, Upul K ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

Addiction; Dependence; Dopamine; Drug self administration; Ethanol; In vivo microdialysis; Nicotine; Nicotinic receptors; NMDA receptors; Opioid receptors; Opioids; Serotonin; Sigma2 receptors; Stimulants

Indexed keywords

18 METHOXYCORONARIDINE; ALCOHOL; CENTRAL STIMULANT AGENT; DOPAMINE; IBOGAINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINE; NICOTINIC RECEPTOR; OPIATE; OPIATE RECEPTOR; SEROTONIN; SIGMA OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; CARDIOVASCULAR EFFECT; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; FEMALE; NEUROTOXICITY; NONHUMAN; NUCLEUS ACCUMBENS; RAT; REVIEW;

EID: 0032885961     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1999.tb00084.x     Document Type: Review

References (42)

1. Ahmed SH, Koob GF. Transition from moderate to excessive drug intake: Change in hedonic set point. Science 1998;282:298-300.
2. Badio B, Padgett WL, Daly JW. Ibogaine: A potent noncompetitive blocker of ganglionic/neuronal nicotinic receptors. Mol Pharmacol 1997;51:1-5.
3. Bandarage UK, Kuehne ME, Glick SD. Total synthesis of racemic albifloranine and its anti-addictive congeners including 18-methoxycoronaridine. Submitted for publication.
4. 2 receptor-selective ligands with moderate affinity. Eur J Pharmacol 1995;279: R1-R3.
5. Cappendijk SLT, Dzoljic MR. Inhibitory effects of ibogaine on cocaine self-administration in rats. Eur J Pharmacol 1993;241:261-265.
6. Deecher DC, Teitler M, Soderlund DM, Bornmann WG, Kuehne ME, Glick SD. Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies. Brain Res 1992;571:242-247.
7. Dhahir HI. A comparative study of the toxicity of ibogaine and serotonin. Unpublished doctoral thesis, Indiana University, 1971; 1-151.
8. Dzoijic ED, Kaplan CD, Dzoljic MR. Effect of ibogaine on naloxone precipitated withdrawal syndrome in chronic morphine dependent rats. Arch Int Pharmacodyn 1988;294:64-70.
9. Glick SD, Kuehne ME, Maisonneuve IM, Bandarage UK, Molinari HH. 18- Methoxycoronaridine, a non-toxic iboga alkaloid congener: Effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats. Brain Res 1996;719:29-35.
10. Glick SD, Kuehne ME, Raucci J, et al. Effects of iboga alkaloids on morphine and cocaine self-administration in rats: Relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. Brain Res 1994;657:14-22.
11. Glick SD, Maisonneuve IM, Raucci J, Archer S. Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Res 1995;681:147-152.
12. Glick SD, Maisonneuve IM, Visker KE, Fritz KA, Bandarage UK, Kuehne ME. 18-Methoxycoronaridine attenuates nicotine-induced dopamine release and nicotine preferences in rats. Psychopharmacology 1998;139:274-280.
13. Glick SD, Pearl SM, Cai Z, Maisonneuve IM. Ibogaine-like effects of noribogaine in rats. Brain Res 1996;713:294-297.
14. Glick SD, Rossman K, Rao NC, Maisonneuve IM, Carlson JN. Effects of ibogaine on acute signs of morphine withdrawal in rats: Independence from tremor. Neuropharmacology 1992;31:497-500.
15. Glick SD, Rossman K, Steindorf S, Carlson JN. Effects and after-effects of ibogaine on morphine self-administration in rats. Eur J Pharmacol 1991;195:341-345.
16. Hough LB, Pearl SM, Glick SD. Tissue distribution of ibogaine after intraperitoneal and subcutaneous administration. Life Sci 1996;58:PL119-122.
17. Kosten TR, Kleber HD, Morgan C. Role of opioid antagonists in treating intravenous cocaine abuse. Life Sci 1989;44:887-892.
18. Layer RT, Skolnick P, Bertha CM, Bandarage UK, Kuehne ME, Popik P. Structurally modified ibogaine analogs exhibit differing affinities for NMDA receptors. Eur J Pharmacol 1996;309:159-165.
19. Le Men J, Taylor WI. A uniform numbering system for indole alkaloids. Experientia 1965;21:508-510.
20. 2 receptors. Life Sci 1995;57:PL57-62.
21. Maisonneuve IM, Glick SD. Interactions between ibogaine and cocaine in rats: In vivo microdialysis and motor behavior. Eur J Pharmacol 1992;212:263-266.
22. Maisonneuve IM, Keller RW, Glick SD. Interactions between ibogaine, a potential anti-addictive agent, and morphine: In vivo microdialysis study. Eur J Pharmacol 1991;199:35-42.
23. Maisonneuve IM, Mann GL, Deibel CR, Glick SD. Ibogaine and the dopaminergic response to nicotine. Pschopharmacology 1997;129:206-214.
24. Maisonneuve IM, Rossman KL, Keller RW, Glick SD. Acute and prolonged effects of ibogaine on brain dopamine metabolism and morphine-induced locomotor activity in rats. Brain Res 1992;575:69-73.
25. Markou A, Weiss F, Gold LH, Caine SB, Schulteis G, Koob G. Animal models of craving. Psychopharmacology 1993;112:163-182.
26. Mash DC, Staley JK, Pablo JP, Holohean AM, Hackman JC, Davidoff RA. Properties of ibogaine and its principal metabolite (12-hydroxyibogamine) at the MK-801 binding site of the NMDA receptor complex. Neurosci Lett 1995;192:53-56.
27. Molinari HH, Maisonneuve IM, Glick SD. Ibogaine neurotoxicity: A re-evaluation. Brain Res 1996;737:255-262.
28. O'Hearn E, Long DB, Molliver ME. Ibogaine induces glial activation in parasagittal zones of the cerebellum. Neuroreport 1993;4:299-302.
29. O'Hearn E, Molliver ME. Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after ibogaine or harmaline. Neuroscience 1993;55:303-310.
30. Pearl SM, Herrick-Davis K, Teitler M, Glick SD. Radioligand binding study of noribogaine, a likely metabolite of ibogaine. Brain Res 1995;675:342-344.
31. Pearl SM, Hough LB, Boyd DL, Glick SD. Sex differences in ibogaine antagonism of morphine-induced locomotor acitvity and in ibogaine brain levels and metabolism. Pharmacol Biochem Behav 1997;57:809-815.
32. Popik P, Layer RT, Fossom LH, et al. NMDA antagonist properties of the putative antiaddictive drug, ibogaine. J Pharmacol Exp Ther 1995;275:753-760.
33. Reid LR, Glick SD, Menkens KA, French ED, Bilsky EJ, Porreca F. Cocaine self-administration and naltrindole, a delta-selective opioid antagonist. Neuroreport 1995;6:1409-1412.
34. Repke DB, Artis DR, Nelson JT, Wong EHF. Abbreviated ibogaine congeners. Synthesis and reactions of tropan-3-yl-2 and -3-indoles. Investigation of an unusual isomerization of 2-substituted indoles using computational and spectroscopic techniques. J Org Chem 1994;59:2164-2171.
35. Rezvani AH, Overstreet DH, Lee YW. Attenuation of alcohol intake by ibogaine in three strains of alcohol-preferring rats. Pharmacol Biochem Behav 1995;52:615-620.
36. Rezvani AH, Overstreet DH, Yang Y, et al. Attenuation of alcohol consumption by a novel non-toxic ibogaine analog (18-methoxycoronaridine) in alcohol preferring rats. Pharmacol Biochem Behav 1997;58:615-619.
37. Rho B, Glick SD. Effects of 18-methoxycoronaridine on acute signs of morphine withdrawal in rats. Neuroreport 1998;9:1283-1285.
38. Schneider AS, Nagel JE, Mah SJ. Ibogaine selectively inhibits nicotinic receptor-mediated catecholamine release. Eur J Pharmacol 1996;317:R1-R2.
39. Staley JK, Ouyang Q, Pablo J, et al. Pharmacological screen for activities of 12-hydroxyibogamine: A primary metabolite of the indole alkaloid ibogaine. Psychopharmacology 1996;127:10-18.
40. Sweetnam PM, Lancaster J, Snowman A, et al. Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity. Psychopharmacology 1995;18:369-376.
41. Vilner BJ, Bandarage UK, Kuehne ME, Bertha CM, Bowen WD. The neurotoxic effect of iboga alkaloids may be mediated by sigma-2 receptors. NIDA Res Monogr 1998;178:235.
42. Wet D, Maisonneuve IM, Kuehne ME, Glick SD. Acute iboga alkaloid effects on extracellular serotonin (S-HT) levels in nucleus accumbens and striatum in rats. Brain Res 1998;800:260-268.